{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:18:31Z","timestamp":1790043511572,"version":"4.0.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ejps.2022.106162","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T04:38:47Z","timestamp":1646368727000},"page":"106162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Pharmacokinetics, tissue distribution and excretion of compound 6c, a novel DPP-4 inhibitor, following intragastric administration in rats by ultra-performance liquid chromatography-tandem mass spectrometry"],"prefix":"10.1016","volume":"173","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6677-7061","authenticated-orcid":false,"given":"Lin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejps.2022.106162_bib0002","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.beem.2007.07.005","article-title":"DPP-4 inhibitors","volume":"21","author":"Ahr\u00e9n","year":"2007","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejps.2022.106162_bib0009","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","article-title":"IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045","volume":"138","author":"Cho","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejps.2022.106162_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107981","article-title":"Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials","volume":"159","author":"Dicembrini","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"5","key":"10.1016\/j.ejps.2022.106162_bib0014","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1021\/acs.jmedchem.8b01491","article-title":"Discovery of a natural-product-derived preclinical candidate for once-weekly treatment of type 2 diabetes","volume":"62","author":"Li","year":"2019","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.ejps.2022.106162_bib0007","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.3390\/ijerph16152720","article-title":"The role of DPP-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: when to select, what to expect","volume":"16","author":"Makrilakis","year":"2019","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"1","key":"10.1016\/j.ejps.2022.106162_bib0008","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s13300-012-0014-7","article-title":"Drug-induced generalized skin eruption in a diabetes mellitus patient receiving a dipeptidyl peptidase-4 inhibitor plus metformin","volume":"3","author":"Nakatani","year":"2012","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.ejps.2022.106162_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"8","key":"10.1016\/j.ejps.2022.106162_bib0001","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1463-1326.2010.01212.x","article-title":"Pharmacokinetics of dipeptidylpeptidase-4 inhibitors","volume":"12","author":"Scheen","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejps.2022.106162_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112850","article-title":"Structural optimization of pyrazolo[1,5-a]pyrimidine derivatives as potent and highly selective DPP-4 inhibitors","volume":"208","author":"Shen","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2022.106162_bib0015","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/bs.apha.2018.04.005","article-title":"Pharmacogenetics of antidiabetic drugs","volume":"83","author":"Srinivasan","year":"2018","journal-title":"Adv. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejps.2022.106162_bib0010","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2174\/22123911MTA5pMzA20","article-title":"Efficacy and cardiovascular safety of DPP-4 inhibitors","volume":"16","author":"Subrahmanyan","year":"2021","journal-title":"Curr. Drug Saf."},{"issue":"4","key":"10.1016\/j.ejps.2022.106162_bib0013","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/dc12-1805","article-title":"Type 2 diabetes: etiology and reversibility","volume":"36","author":"Taylor","year":"2013","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ejps.2022.106162_bib0011","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.beem.2009.03.004","article-title":"Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)","volume":"23","author":"Thornberry","year":"2009","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"19","key":"10.1016\/j.ejps.2022.106162_bib0016","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.2169\/internalmedicine.8184-16","article-title":"Efficacy and patient satisfaction of the weekly DPP-4 inhibitors trelagliptin and omarigliptin in 80 Japanese patients with type 2 diabetes","volume":"56","author":"Tosaki","year":"2017","journal-title":"Intern. Med."},{"issue":"13","key":"10.1016\/j.ejps.2022.106162_bib0003","doi-asserted-by":"crossref","first-page":"7108","DOI":"10.1021\/acs.jmedchem.0c00374","article-title":"Design, synthesis, and evaluation of a series of novel super long-acting DPP-4 inhibitors for the treatment of type 2 diabetes","volume":"63","author":"Zhang","year":"2020","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejps.2022.106162_bib0004","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/14728222.2020.1721468","article-title":"The emerging role of dipeptidyl-peptidase-4 as a therapeutic target in lung disease","volume":"24","author":"Zou","year":"2020","journal-title":"Expert Opin. Ther. Targets"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098722000471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098722000471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:01:01Z","timestamp":1760529661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098722000471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":16,"alternative-id":["S0928098722000471"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2022.106162","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics, tissue distribution and excretion of compound 6c, a novel DPP-4 inhibitor, following intragastric administration in rats by ultra-performance liquid chromatography-tandem mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2022.106162","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106162"}}